The global induced pluripotent stem cells market is expected to grow at a CAGR of 16.5% during the forecast period, from 2021 to 2030. The human iPSCs segment accounted for 89% of the total market share in 2018 and is expected to maintain its dominance throughout the forecast period. The human iPSCs segment is projected to grow at a CAGR of 17.2% during the forecast period, from 2021 to 2030.
The mouse iPSCs segment accounted for 11% of the total market share in 2018 and is expected to maintain its dominance throughout the forecast period. The mouse iPSCs segment is projected to grow at a CAGR of 18.8%, from 2021-2030, which will be higher than that of human iPSCs (17%).
Some Of The Growth Factors Of This Market:
- The global iPSC market is driven by factors such as increasing prevalence of chronic diseases, rising demand for regenerative medicine products, technological advancements in stem cell research and development, and growing government support for stem cell research programs.
- Increasing awareness about the benefits associated with regenerative medicine products has led to an increase in demand for these products which has resulted in an increase in the number of clinical trials being conducted globally on various types of diseases including cancer, cardiovascular disease (CVD), diabetes mellitus type 2 (DM), Alzheimer's disease (AD), Parkinson's disease (PD) etc, which are driving growth prospects for this market over the forecast period from 2017-2025 4a) In addition, increasing government support towards funding research programs related to regenerative medicine has also contributed towards growth prospects over the forecast period from 2017-2025; 4b) Technological advancements have led to increased efficiency in production processes which has reduced costs associated with manufacturing these products thereby making them more affordable; 4c) Rising incidence rates among patients suffering from chronic diseases such as cancer have also contributed towards growth prospects over the forecast period from 2017-2025; 4d) Increasing awareness about benefits associated with regenerative medicine products among patients suffering from chronic diseases such as cancer has led them towards opting for these treatments thereby contributing towards growth prospects over the forecast period from 2017-2025; 5) Increasing adoption rates among healthcare providers owing to their ability provide better treatment options than conventional therapies will also contribute towards growth prospects over the forecast period from 2017-2025.
Industry Growth Insights published a new data on “Induced Pluripotent Stem Cells (iPSCs) Market”. The research report is titled “Induced Pluripotent Stem Cells (iPSCs) Market research by Types (Human iPSCs, Mouse iPSCs, Human iPSCs had a market share of 89% in 2018, followed by Mouse iPSCs., Induced Pluripotent Stem Cells (iPSCs), By Applications (Academic Research, Drug Development and Discovery, Toxicity Screening, Regenerative Medicine), By Players/Companies Fujifilm Holding Corporation (CDI), Ncardia, Sumitomo Dainippon Pharma, Astellas Pharma Inc, Fate Therapeutics, Inc, Pluricell Biotech, Cell Inspire Biotechnology, ReproCELL, Induced Pluripotent Stem Cells (iPSCs”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Induced Pluripotent Stem Cells (iPSCs) Market Research Report
By Type
Human iPSCs, Mouse iPSCs, Human iPSCs had a market share of 89% in 2018, followed by Mouse iPSCs., Induced Pluripotent Stem Cells (iPSCs
By Application
Academic Research, Drug Development and Discovery, Toxicity Screening, Regenerative Medicine
By Companies
Fujifilm Holding Corporation (CDI), Ncardia, Sumitomo Dainippon Pharma, Astellas Pharma Inc, Fate Therapeutics, Inc, Pluricell Biotech, Cell Inspire Biotechnology, ReproCELL, Induced Pluripotent Stem Cells (iPSCs
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
231
Number of Tables & Figures
162
Customization Available
Yes, the report can be customized as per your need.
 Industry Outlook.svg)
Global Induced Pluripotent Stem Cells (iPSCs) Market Report Segments:
The global Induced Pluripotent Stem Cells (iPSCs) market is segmented on the basis of:
Types
Human iPSCs, Mouse iPSCs, Human iPSCs had a market share of 89% in 2018, followed by Mouse iPSCs., Induced Pluripotent Stem Cells (iPSCs
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Academic Research, Drug Development and Discovery, Toxicity Screening, Regenerative Medicine
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Fujifilm Holding Corporation (CDI)
- Ncardia
- Sumitomo Dainippon Pharma
- Astellas Pharma Inc
- Fate Therapeutics, Inc
- Pluricell Biotech
- Cell Inspire Biotechnology
- ReproCELL
- Induced Pluripotent Stem Cells (iPSCs
 Market Overview.svg)
Highlights of The Induced Pluripotent Stem Cells (iPSCs) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Human iPSCs
- Mouse iPSCs
- Human iPSCs had a market share of 89% in 2018, followed by Mouse iPSCs.
- Induced Pluripotent Stem Cells (iPSCs
- By Application:
- Academic Research
- Drug Development and Discovery
- Toxicity Screening
- Regenerative Medicine
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Induced Pluripotent Stem Cells (iPSCs) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Induced pluripotent stem cells (iPSCs) are a type of cell that can be induced to become any type of cell in the body. They are created by taking adult cells and forcing them to revert back to a more primitive state, which allows them to become pluripotent. This means that they can create any kind of tissue in the body, including muscle, nerve, and blood cells.
Some of the major players in the induced pluripotent stem cells (ipscs) market are Fujifilm Holding Corporation (CDI), Ncardia, Sumitomo Dainippon Pharma, Astellas Pharma Inc, Fate Therapeutics, Inc, Pluricell Biotech, Cell Inspire Biotechnology, ReproCELL, Induced Pluripotent Stem Cells (iPSCs.
The induced pluripotent stem cells (ipscs) market is expected to grow at a compound annual growth rate of 16.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Induced Pluripotent Stem Cells (iPSCs) Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Induced Pluripotent Stem Cells (iPSCs) Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Induced Pluripotent Stem Cells (iPSCs) Market - Supply Chain
4.5. Global Induced Pluripotent Stem Cells (iPSCs) Market Forecast
4.5.1. Induced Pluripotent Stem Cells (iPSCs) Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Induced Pluripotent Stem Cells (iPSCs) Market Size (000 Units) and Y-o-Y Growth
4.5.3. Induced Pluripotent Stem Cells (iPSCs) Market Absolute $ Opportunity
5. Global Induced Pluripotent Stem Cells (iPSCs) Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Induced Pluripotent Stem Cells (iPSCs) Market Size and Volume Forecast by Type
5.3.1. Human iPSCs
5.3.2. Mouse iPSCs
5.3.3. Human iPSCs had a market share of 89% in 2018, followed by Mouse iPSCs.
5.3.4. Induced Pluripotent Stem Cells (iPSCs
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Induced Pluripotent Stem Cells (iPSCs) Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Induced Pluripotent Stem Cells (iPSCs) Market Size and Volume Forecast by Application
6.3.1. Academic Research
6.3.2. Drug Development and Discovery
6.3.3. Toxicity Screening
6.3.4. Regenerative Medicine
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Induced Pluripotent Stem Cells (iPSCs) Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Induced Pluripotent Stem Cells (iPSCs) Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Induced Pluripotent Stem Cells (iPSCs) Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Induced Pluripotent Stem Cells (iPSCs) Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Induced Pluripotent Stem Cells (iPSCs) Demand Share Forecast, 2019-2026
9. North America Induced Pluripotent Stem Cells (iPSCs) Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Induced Pluripotent Stem Cells (iPSCs) Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Induced Pluripotent Stem Cells (iPSCs) Market Size and Volume Forecast by Application
9.4.1. Academic Research
9.4.2. Drug Development and Discovery
9.4.3. Toxicity Screening
9.4.4. Regenerative Medicine
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Induced Pluripotent Stem Cells (iPSCs) Market Size and Volume Forecast by Type
9.7.1. Human iPSCs
9.7.2. Mouse iPSCs
9.7.3. Human iPSCs had a market share of 89% in 2018, followed by Mouse iPSCs.
9.7.4. Induced Pluripotent Stem Cells (iPSCs
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Induced Pluripotent Stem Cells (iPSCs) Demand Share Forecast, 2019-2026
10. Latin America Induced Pluripotent Stem Cells (iPSCs) Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Induced Pluripotent Stem Cells (iPSCs) Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Induced Pluripotent Stem Cells (iPSCs) Market Size and Volume Forecast by Application
10.4.1. Academic Research
10.4.2. Drug Development and Discovery
10.4.3. Toxicity Screening
10.4.4. Regenerative Medicine
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Induced Pluripotent Stem Cells (iPSCs) Market Size and Volume Forecast by Type
10.7.1. Human iPSCs
10.7.2. Mouse iPSCs
10.7.3. Human iPSCs had a market share of 89% in 2018, followed by Mouse iPSCs.
10.7.4. Induced Pluripotent Stem Cells (iPSCs
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Induced Pluripotent Stem Cells (iPSCs) Demand Share Forecast, 2019-2026
11. Europe Induced Pluripotent Stem Cells (iPSCs) Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Induced Pluripotent Stem Cells (iPSCs) Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Induced Pluripotent Stem Cells (iPSCs) Market Size and Volume Forecast by Application
11.4.1. Academic Research
11.4.2. Drug Development and Discovery
11.4.3. Toxicity Screening
11.4.4. Regenerative Medicine
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Induced Pluripotent Stem Cells (iPSCs) Market Size and Volume Forecast by Type
11.7.1. Human iPSCs
11.7.2. Mouse iPSCs
11.7.3. Human iPSCs had a market share of 89% in 2018, followed by Mouse iPSCs.
11.7.4. Induced Pluripotent Stem Cells (iPSCs
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Induced Pluripotent Stem Cells (iPSCs) Demand Share, 2019-2026
12. Asia Pacific Induced Pluripotent Stem Cells (iPSCs) Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Induced Pluripotent Stem Cells (iPSCs) Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Induced Pluripotent Stem Cells (iPSCs) Market Size and Volume Forecast by Application
12.4.1. Academic Research
12.4.2. Drug Development and Discovery
12.4.3. Toxicity Screening
12.4.4. Regenerative Medicine
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Induced Pluripotent Stem Cells (iPSCs) Market Size and Volume Forecast by Type
12.7.1. Human iPSCs
12.7.2. Mouse iPSCs
12.7.3. Human iPSCs had a market share of 89% in 2018, followed by Mouse iPSCs.
12.7.4. Induced Pluripotent Stem Cells (iPSCs
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Induced Pluripotent Stem Cells (iPSCs) Demand Share, 2019-2026
13. Middle East & Africa Induced Pluripotent Stem Cells (iPSCs) Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Induced Pluripotent Stem Cells (iPSCs) Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Induced Pluripotent Stem Cells (iPSCs) Market Size and Volume Forecast by Application
13.4.1. Academic Research
13.4.2. Drug Development and Discovery
13.4.3. Toxicity Screening
13.4.4. Regenerative Medicine
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Induced Pluripotent Stem Cells (iPSCs) Market Size and Volume Forecast by Type
13.7.1. Human iPSCs
13.7.2. Mouse iPSCs
13.7.3. Human iPSCs had a market share of 89% in 2018, followed by Mouse iPSCs.
13.7.4. Induced Pluripotent Stem Cells (iPSCs
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Induced Pluripotent Stem Cells (iPSCs) Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Induced Pluripotent Stem Cells (iPSCs) Market: Market Share Analysis
14.2. Induced Pluripotent Stem Cells (iPSCs) Distributors and Customers
14.3. Induced Pluripotent Stem Cells (iPSCs) Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Fujifilm Holding Corporation (CDI)
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Ncardia
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Sumitomo Dainippon Pharma
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Astellas Pharma Inc
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Fate Therapeutics, Inc
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Pluricell Biotech
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Cell Inspire Biotechnology
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. ReproCELL
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Induced Pluripotent Stem Cells (iPSCs
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
&
